Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.
about
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraRituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow.Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases.A case of mixed connective tissue disease complicated with thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura: survival by "giving a dam"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.Rituximab in the treatment of autoimmune haematological disorders.Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndromeIdiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndromeHow I treat refractory thrombotic thrombocytopenic purpura.Why Do We Need ADAMTS13?Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentCross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Rituximab in immunologic glomerular diseases.Rituximab in patients with refractory thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpuraRituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus
P2860
Q28080631-F742FD98-55D2-4B64-A54F-CE481718D553Q33346680-BD3AF6AA-EDBA-4F5A-A132-BB66C1DE9179Q33347147-316A9FAF-4E05-418D-801F-A735FCAFFDD3Q33359900-4531BE7E-6F35-401C-A6D4-FB4E5A9D194BQ33361703-36238291-BC95-4E90-B638-8960D2613F3AQ33366172-6483561D-9913-4E06-824A-73DB66779A90Q33368176-B1E917BB-0ED3-42E0-B5B8-2759639B81E3Q33368490-11233C4C-9ED5-4CB9-903D-A3012A1A41D6Q33368709-3FBAF413-C463-4745-8CF5-EFC86657B9E5Q33369798-7FABE931-67B7-4E5E-BEAC-12D220F61B73Q33373067-2B7F5F4B-AE34-4B95-AB28-20559F2C5B7BQ33373912-A49EAA6F-61D9-4D6D-95B8-1471AB03E80FQ33374294-BCEE854E-27B5-48BE-A453-53CF15C5F73CQ33378854-A03CD608-86FB-402A-8547-9D7558287D80Q33389561-105056D7-59AC-4813-864E-0A76A68FED42Q33391086-E3119720-065C-4C92-A395-C56EFA1F2729Q33398967-D93CCADC-ACBD-4B86-9834-82BD7A6A1143Q33400631-76BF82C6-7EFC-4DF4-929D-EACD74824CE0Q33401010-872AE5C9-05C1-4675-AD75-8DF54B5BD5CBQ33409112-03005F11-09FF-49D9-81CF-D9345290BF0CQ33412445-C104F242-04F0-4DF5-805D-07D0F190DDFBQ33421268-EBAD25AC-B18B-4F51-B998-5DCE3418410BQ35062975-D451DF5A-E6A7-48C6-90EB-9DFA6E9E72A2Q36338254-998BA255-F7A5-49F0-B320-E813BF8A80F9Q37040458-ECB17CA4-3BC4-405E-BE1D-4765B803B8C7Q37843939-14839B70-285D-43D0-9009-AC97E0567735Q37989298-29A6E62F-44BF-4B4A-8FCD-D4E26D099835Q47730276-CD963F56-A33D-478B-A147-CA6A23F868BDQ57591162-8C008032-7E4B-4F3D-8D03-969B972F33DFQ58482137-3269EF70-5819-4605-9C70-A7B6F4B7C03E
P2860
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Successful treatment of severe ...... monoclonal antibody rituximab.
@ast
Successful treatment of severe ...... monoclonal antibody rituximab.
@en
type
label
Successful treatment of severe ...... monoclonal antibody rituximab.
@ast
Successful treatment of severe ...... monoclonal antibody rituximab.
@en
prefLabel
Successful treatment of severe ...... monoclonal antibody rituximab.
@ast
Successful treatment of severe ...... monoclonal antibody rituximab.
@en
P2093
P2860
P356
P1476
Successful treatment of severe ...... monoclonal antibody rituximab.
@en
P2093
Andreas Draube
Armin Schulz
Christof Scheid
Dietmar Söhngen
Jens Chemnitz
Peter Staib
Volker Diehl
P2860
P304
P356
10.1002/AJH.10204
P577
2002-10-01T00:00:00Z